Novavax, Inc. submitted a request to expand the conditional marketing authorization (CMA) of Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) in the EU for adolescents aged 12 through 17 years.   The submission includes clinical data from the ongoing pediatric expansion of PREVENT-19, a pivotal Phase 3 trial of 2,247 adolescents aged 12 through 17 years across 73 sites in the U.S., to evaluate the safety, and efficacy of Novavax’ COVID-19 vaccine. The vaccine, also known as NVX-CoV23...